Bausch + Lomb (BLCO) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Bausch + Lomb Revenue Highlights


Latest Revenue (Y)

$4.15B

Latest Revenue (Q)

$1.20B

Main Segment (Y)

Device Products

Main Geography (Y)

United States and Puerto Rico

Bausch + Lomb Revenue by Period


Bausch + Lomb Revenue by Year

DateRevenueChange
2023-12-31$4.15B10.03%
2022-12-31$3.77B0.08%
2021-12-31$3.77B10.35%
2020-12-31$3.41B-9.69%
2019-12-31$3.78B3.08%
2018-12-31$3.67B-

Bausch + Lomb generated $4.15B in revenue during NA 2023, up 10.03% compared to the previous quarter, and up 113.12% compared to the same period a year ago.

Bausch + Lomb Revenue by Quarter

DateRevenueChange
2024-09-30$1.20B-1.64%
2024-06-30$1.22B10.65%
2024-03-31$1.10B-6.31%
2023-12-31$1.17B16.48%
2023-09-30$1.01B-2.71%
2023-06-30$1.03B11.17%
2023-03-31$931.00M-6.53%
2022-12-31$996.00M5.73%
2022-09-30$942.00M0.11%
2022-06-30$941.00M5.85%
2022-03-31$889.00M-11.19%
2021-12-31$1.00B5.48%
2021-09-30$949.00M1.61%
2021-06-30$934.00M6.02%
2021-03-31$881.00M-6.67%
2020-12-31$944.00M3.06%
2020-09-30$916.00M18.04%
2020-06-30$776.00M-
2020-03-31$776.00M-

Bausch + Lomb generated $1.20B in revenue during Q3 2024, up -1.64% compared to the previous quarter, and up 115.56% compared to the same period a year ago.

Bausch + Lomb Revenue Breakdown


Bausch + Lomb Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22
Device Products$1.65B-
Over the Counter Products$1.61B-
Pharmaceutical Products$618.00M-
Branded and Other Generic Products$252.00M-
Other Revenues$15.00M-
Product-$3.75B
Product and Service, Other-$22.00M

Bausch + Lomb's latest annual revenue breakdown by segment (product or service), as of Dec 23: Device Products (39.80%), Over the Counter Products (38.86%), Pharmaceutical Products (14.91%), Branded and Other Generic Products (6.08%), and Other Revenues (0.36%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
Branded and Other Generic Products$70.00M$76.00M$66.00M$180.00M$72.00M------
Device Products$455.00M$445.00M$424.00M$1.24B$411.00M------
Other Revenues$4.00M$3.00M$5.00M$12.00M$3.00M------
Over the Counter Products$420.00M$447.00M$395.00M$1.20B$408.00M------
Pharmaceutical Products$247.00M$245.00M$209.00M$505.00M$113.00M------
Product-----$1.03B$928.00M$991.00M$937.00M$935.00M$883.00M
Product and Service, Other-----$4.00M$3.00M$5.00M$5.00M$6.00M$6.00M

Bausch + Lomb's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Device Products (38.04%), Over the Counter Products (35.12%), Pharmaceutical Products (20.65%), Branded and Other Generic Products (5.85%), and Other Revenues (0.33%).

Bausch + Lomb Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22
JAPAN$187.00M$192.00M
KOREA, REPUBLIC OF$46.00M$44.00M
CANADA$110.00M$101.00M
CHINA$344.00M$343.00M
FRANCE$210.00M$195.00M
GERMANY$147.00M$138.00M
MEXICO$68.00M$55.00M
Other Countries$655.00M$572.00M
POLAND$51.00M$44.00M
SPAIN$85.00M$77.00M
United States and Puerto Rico$1.93B$1.70B
ITALY$82.00M$72.00M

Bausch + Lomb's latest annual revenue breakdown by geography, as of Dec 23: United States and Puerto Rico (49.35%), Other Countries (16.71%), CHINA (8.78%), FRANCE (5.36%), JAPAN (4.77%), GERMANY (3.75%), CANADA (2.81%), SPAIN (2.17%), ITALY (2.09%), MEXICO (1.74%), POLAND (1.30%), and KOREA, REPUBLIC OF (1.17%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
MEXICO$18.00M$20.00M$17.00M$18.00M$19.00M$15.00M$16.00M$16.00M$14.00M$14.00M$11.00M
KOREA, REPUBLIC OF$12.00M$11.00M$12.00M$11.00M$12.00M$12.00M$11.00M$11.00M$11.00M$11.00M$11.00M
JAPAN$45.00M$43.00M$42.00M$48.00M$45.00M$46.00M$48.00M$49.00M$46.00M$47.00M$50.00M
FRANCE$52.00M$64.00M$60.00M$45.00M$47.00M$62.00M$56.00M$41.00M$43.00M$56.00M$55.00M
CANADA$33.00M$32.00M$28.00M$30.00M$27.00M$27.00M$26.00M$28.00M$27.00M$24.00M$22.00M
CHINA$92.00M$93.00M$77.00M$94.00M$87.00M$89.00M$74.00M$92.00M$93.00M$76.00M$82.00M
ITALY$22.00M$23.00M$23.00M$21.00M$19.00M$22.00M$20.00M$15.00M$16.00M$21.00M$20.00M
GERMANY$38.00M$40.00M$42.00M$32.00M$33.00M$40.00M$42.00M$32.00M$30.00M$33.00M$43.00M
United States and Puerto Rico$609.00M$610.00M$537.00M$593.00M$471.00M$466.00M$404.00M$454.00M$425.00M$430.00M$386.00M
SPAIN$20.00M$25.00M$21.00M$23.00M$18.00M$24.00M$20.00M$21.00M$15.00M$22.00M$19.00M
POLAND$17.00M$18.00M$15.00M$14.00M$11.00M$14.00M$12.00M$11.00M$10.00M$12.00M$11.00M
Other Countries$174.00M$175.00M$166.00M$214.00M$150.00M$152.00M$139.00M$157.00M$142.00M$138.00M$126.00M
AUSTRALIA----$11.00M$11.00M$10.00M----
SWEDEN----------$9.00M

Bausch + Lomb's latest quarterly revenue breakdown by geography, as of Sep 24: United States and Puerto Rico (53.80%), Other Countries (15.37%), CHINA (8.13%), FRANCE (4.59%), JAPAN (3.98%), GERMANY (3.36%), CANADA (2.92%), ITALY (1.94%), SPAIN (1.77%), MEXICO (1.59%), POLAND (1.50%), and KOREA, REPUBLIC OF (1.06%).

Bausch + Lomb Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BDXBecton, Dickinson and Company$19.37B$4.99B
ALCAlcon$10.09B$2.46B
RMDResMed$4.69B$1.22B
BLCOBausch + Lomb$4.15B$1.20B
HOLXHologic$4.03B$1.01B
COOCooper Companies$3.59B$1.00B
ATRAptarGroup$3.49B$909.29M
TFXTeleflex$2.97B$764.38M
WSTWest Pharmaceutical Services$2.95B$746.90M
ICUIICU Medical$2.26B$596.46M
HAEHaemonetics$1.31B$336.17M
ATRCAtriCure$399.25M$115.91M
ANGOAngioDynamics$303.91M$67.49M
AKYAAkoya Biosciences$96.63M$23.16M
ATRIAtrion-$48.77M

BLCO Revenue FAQ


Bausch + Lomb's yearly revenue for 2023 was $4.15B, representing an increase of 10.03% compared to 2022. The company's yearly revenue for 2022 was $3.77B, representing an increase of 0.08% compared to 2021. BLCO's yearly revenue for 2021 was $3.76B, representing an increase of 10.35% compared to 2020.

Bausch + Lomb's quarterly revenue for Q3 2024 was $1.2B, a -1.64% decrease from the previous quarter (Q2 2024), and a 18.77% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.22B, a 10.65% increase from the previous quarter (Q1 2024), and a 17.49% increase year-over-year (Q2 2023). BLCO's quarterly revenue for Q1 2024 was $1.1B, a -6.31% decrease from the previous quarter (Q4 2023), and a 18.05% increase year-over-year (Q1 2023).

Bausch + Lomb's revenue growth rate for the last 3 years (2021-2023) was 10.12%, and for the last 5 years (2019-2023) was 9.74%.

Bausch + Lomb's revenue streams in c 23 are Device Products, Over the Counter Products, Pharmaceutical Products, Branded and Other Generic Products, and Other Revenues. Device Products generated $1.65B in revenue, accounting 39.80% of the company's total revenue Over the Counter Products generated $1.61B in revenue, accounting 38.86% of the company's total revenue Pharmaceutical Products generated $618M in revenue, accounting 14.91% of the company's total revenue Branded and Other Generic Products generated $252M in revenue, accounting 6.08% of the company's total revenue Other Revenues generated $15M in revenue, accounting 0.36% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of Bausch + Lomb was Device Products. This segment made a revenue of $1.65B, representing 39.80% of the company's total revenue.